EMERYVILLE, Calif., July 15, 2010 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY) (www.novabaypharma.com) announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office on a patent application for a broad portfolio of anti-infective compounds, including NVC-612. The patent will broaden protection for NovaBay’s first-in-class Aganocide® family of compounds, which are designed to fight infections without causing drug resistance.
